Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aα

Molecular Cancer Therapeutics

Volumn 5, Issue 11, 2006, Pages 2727-2736

  Boness, Kathy ^a   Aragon, Ileana V ^a   Rutland, Beth ^b   Ofori Acquah, Solomon ^b   Dean, Nicholas M ^c   Honkanen, Richard E ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CANTHARIDIN; DNA; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2AALPHA; PHOSPHOPROTEIN PHOSPHATASE 2ABETA; SMALL INTERFERING RNA;

ANAPHASE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL POPULATION; CELL SYNCHRONIZATION; CHROMOSOME ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA REPLICATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; METAPHASE; MICROSCOPY; MITOSIS INHIBITION; MITOSIS SPINDLE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SPINDLE POLE BODY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CANTHARIDIN; CELL CYCLE; CHROMOSOMES, HUMAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; MITOSIS; MITOTIC SPINDLE APPARATUS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES; PHOSPHOPROTEIN PHOSPHATASE; RNA, SMALL INTERFERING; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33845192664     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0273     Document Type: Article

References (33)

1. Wang GS. Medical uses of Mylabris in ancient China and recent studies. J Ethnopharmacol 1989;26:147-62.
2. Oaks WW, Ditunno JF, Magnani T, Levy HA, Mills LC. Cantharidin poisoning. Arch Intern Med 1960;105:574-82.
3. McCluskey A, Sakoff JA. Small molecule inhibitors of serine/threonine protein phosphatases. Mini Rev Mad Chem 2001;1:43-55.
4. McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, Baldwin ML. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 2000;10:1687-90.
5. McCluskey A, Ackland SP, Bowyer MC, et al. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem 2003;31:68-79.
6. Wang CC, Wu CH, Hsieh KJ, Yen KY, Yang LL. Cytotoxic effects of cantharidin on the growth of normal and carcinoma cells. Toxicology 2000;147:77-87.
7. Huan SK, Lee HH, Liu DZ, Wu CC, Wang CC. Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. Toxicology 2006;223:136-43.
8. McCluskey A, Sim AT, Sakoff JA. Serine-threonine protein phosphatase inhibitors; development of potential therapeutic strategies. J Med Chem 2002;45:1151-75.
9. Zhang WD, Zhao HR, Yan Y, Wang XH, Zong ZH, Liu Y. [Apoptosis induced by cantharidin in human pulmonary carcinoma cells A549 and its molecular mechanismsl. Zhonghua Zhong Liu Za Zhi 2005;27:330-4.
10. Huh JE, Kang KS, Chae C, Kim HM, Ahn KS, Kim SH. Roles of p38 and JNK mitogen-activated protein kinase pathways during cantharidin-induced apoptosis in U937 cells. Biochem Pharmacol 2004;67:1811-8.
11. Efferth T, Rauh R, Kahl S, et al. Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol 2005;69:811-8.
12. Graziano MJ, Pessah IN, Matsuzawa M, Casida JE. Partial characterization of specific cantharidin binding sites in mouse tissues. Mol Pharmacol 1988;33:706-12.
13. Eldridge R, Casida JE. Cantharidin effects on protein phosphatases and the phosphorylation state of phosphoproteins in mice. Toxicol Appl Pharmacol 1995;130:95-100.
14. Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 1993;330:283-6.
15. Honkanen RE, Golden T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Mad Chem 2002;9: 2055-75.
16. Hastie CJ, Cohen PT. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. FEBS Lett 1998;431:357-61.
17. Swingle MR, Honkanen RE, Ciszak EM. Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. J Biol Chem 2004;279:33992-9.
18. Buck SB, Hardouin C, Ichikawa S, et al. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. J Am Chem Soc 2003;125:15694-5.
19. Honkanen RE, Zwiller J, Moore RE, et al. Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J Biol Chem 1990;265:19401-4.
20. Chang A, Dean NM, Honkanen RE. Serine/threonine protein phosphatase type 1-γ1 is required for the completion of cytokinesis in human A549 lung carcinoma cells. J Biol Chem 2000;275:1846-54.
21. Balczon RD, Brinkley BR. Tubulin interaction with kinetochore proteins: analysis by in vitro assembly and chemical cross-linking. J Cell Biol 1987;105:855-62.
22. Dean NM, McKay R, Condon TP, Bennett CF. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 1994;269:16416-24.
23. Dean NM, Griffey RH. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1997;7:229-33.
24. Zuo Z, Dean NM, Honkanen RE. Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21 (WAF1/Cip1) and mediate growth arrest. J Biol Chem 1998;273:12250-8.
25. Honkanen RE, Zwiller J, Daily SL, Khatra BS, Dukelow M, Boynton AL. Identification, purification, and characterization of a novel serine/ threonine protein phosphatase from bovine brain. J Biol Chem 1991;266:6614-9.
26. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992;32:329-76.
27. Golden T, Dean NM, Honkanen RE. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue. Microcirculation 2002;9: 51-64.
28. Urban G, Golden T, Aragon IV, et al. Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem 2003;278:9747-53.
29. Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 1998;8:377-85.
30. Zuo Z, Urban G, Scammell JG, et al. Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry 1999;38:8849-57.
31. Nasmyth K. Segregating sister genomes: the molecular biology of chromosome separation. Science 2002;297:559-65.
32. Riedel CG, Katis VL, Katou Y, et al. Protein phosphatase 2A protects centromeric sister chromatid cohesion during meiosis I. Nature 2006;441:35-7.
33. Tang Z, Shu H, Qi W, Mahmood N, Mumby MC, Yu H. PP2A Is required for centromeric localizatin of Sgo1 and proper chromosome segregation. Dev Cell 2006;10:575-85.